PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pivekimab Sunirine→

Pivekimab Sunirine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
CD123-directed antibody-drug conjugate (ADC)indolinobenzodiazepine DNA-alkylating antineoplastic
Mechanism of action
Pivekimab sunirine is a humanised anti-CD123 IgG1 antibody-drug conjugate. After binding to CD123-expressing cells and internalisation, intracellular processing releases the FGN849 indolinobenzodiazepine pseudodimer payload, which alkylates DNA, causes DNA strand breaks and induces apoptosis and cell death.
Indications / reported uses
  • Treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), under the US product indication approved in May 2026.

Sources: https://www.fda.gov/drugs/cancer-approvals/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=508b6ff8-601d-4901-a7a5-816141134054 · https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-decnupaz

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Pivekimab Sunirine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pivekimab Sunirine Permitted Daily Exposure (PDE) report (the Pivekimab Sunirine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pivekimab Sunirine Occupational Exposure Limit (OEL) report (the Pivekimab Sunirine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.